Stay updated on Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial

Sign up to get notified when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    An NIH banner announces a website transition and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-24T12:15:44.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The site revision label in the footer changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T14:02:41.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer now identifies the site revision as v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-10T13:58:36.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error for the study record, with the standard site header and footer visible; this indicates access is blocked to the study page rather than an update to the study information.
    Difference
    0.5%
    Check dated 2026-09-26T18:44:36.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Access to the study page content is blocked by a 403 Forbidden error, replacing the normal study record details. This prevents viewing the study's information, contacts, and locations until the error is resolved.
    Difference
    17%
    Check dated 2026-09-19T22:22:22.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The page footer now shows Revision: v3.6.6, replacing the previous Revision: v3.6.5. This update reflects a maintenance release and does not alter the study details or user-facing navigation.
    Difference
    0.1%
    Check dated 2026-08-29T19:55:39.000Z thumbnail image

Stay in the know with updates to Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.